{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T18:03:27Z","timestamp":1787853807273,"version":"build-2784847793"},"reference-count":39,"publisher":"The Journal of Rheumatology","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Rheumatol"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:sec><jats:title>Objective<\/jats:title><jats:p>The efficacy of tofacitinib (TOF) in the early diagnosis of melanoma differentiation\u2013associated gene 5 (MDA5)\u2013related interstitial lung disease (ILD) has been described. However, whether TOF exposure is associated with a reduced 1-year mortality rate remains undetermined.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Patients diagnosed with MDA5-ILD receiving TOF or tacrolimus (TAC) treatment were included. A Cox proportional hazards model, which was adjusted for age, sex, smoking history, anti-MDA5 antibody titers, and concurrent use of other steroid-sparing agents, was performed to compare all-cause mortality and to investigate the risk factors predicting 1-year mortality rates in the 2 treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>During the study period, 26 patients were treated with TOF and 35 were treated with TAC. The 6-month (38.5% vs 62.9%;<jats:italic>P<\/jats:italic>= 0.03) and 1-year (44.0% vs 65.7%;<jats:italic>P<\/jats:italic>= 0.03) mortality rates in the TOF group were significantly lower than those in the TAC group. There were 13 patients diagnosed with rapidly progressive ILD (RP-ILD) in the TOF group and 22 in the TAC group. The majority of deaths occurred in patients with RP-ILD. The 6-month (76.9% vs 95.5%;<jats:italic>P<\/jats:italic>= 0.02) and 1-year (84.6% vs 100.0%;<jats:italic>P<\/jats:italic>= 0.02) mortality rates of patients with RP-ILD in the TOF group were also lower than those in the TAC group, respectively. The adjusted model showed that TOF exposure was associated with a lower risk for 1-year mortality (hazard ratio 0.44, 95% CI 0.20-0.96;<jats:italic>P<\/jats:italic>= 0.04). However, the incidence of adverse events (73.1% vs 74.3%;<jats:italic>P<\/jats:italic>&gt; 0.99) and medication discontinuation rates (23.1% vs 14.3%;<jats:italic>P<\/jats:italic>= 0.50) in the TOF and TAC groups were similar, respectively.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Our observational study showed that TOF use might have a potential effect on improving the outcomes of MDA5-ILD. Future clinical trials are needed to assess the long-term efficacy and tolerability of TOF.<\/jats:p><\/jats:sec>","DOI":"10.3899\/jrheum.220367","type":"journal-article","created":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T12:21:55Z","timestamp":1660566115000},"page":"1356-1364","source":"Crossref","is-referenced-by-count":43,"title":["A Retrospective Analysis of Outcome in Melanoma Differentiation\u2013Associated Gene 5\u2013Related Interstitial Lung Disease Treated with Tofacitinib or Tacrolimus"],"prefix":"10.3899","volume":"49","author":[{"given":"Li","family":"Fan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huarui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanyi","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lulu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hourong","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yonglong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3165-0623","authenticated-orcid":false,"given":"Jinghong","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2262","published-online":{"date-parts":[[2022,8,15]]},"reference":[{"key":"2023010522252613000_49.12.1356.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrrheum.2018.41"},{"key":"2023010522252613000_49.12.1356.2","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(18)30254-0"},{"key":"2023010522252613000_49.12.1356.3","doi-asserted-by":"publisher","DOI":"10.1002\/art.10794"},{"key":"2023010522252613000_49.12.1356.4","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s11926-013-0359-6","article-title":"Interstitial lung disease in inflammatory myopathies: clinical phenotypes and prognosis","volume":"15","author":"Kiely","year":"2013","journal-title":"Curr Rheumatol Rep"},{"key":"2023010522252613000_49.12.1356.5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2023010522252613000_49.12.1356.6","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.131223"},{"key":"2023010522252613000_49.12.1356.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2012.06.006"},{"key":"2023010522252613000_49.12.1356.8","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8510-y"},{"key":"2023010522252613000_49.12.1356.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2018.12.040"},{"key":"2023010522252613000_49.12.1356.10","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22728"},{"key":"2023010522252613000_49.12.1356.11","doi-asserted-by":"publisher","DOI":"10.1002\/acr.21985"},{"key":"2023010522252613000_49.12.1356.12","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1002\/art.41105","article-title":"Multicenter prospective study of the efficacy and safety of combined immunosuppressive therapy with high-dose glucocorticoid, tacrolimus, and cyclophosphamide in interstitial lung diseases accompanied by anti-melanoma differentiation-associated gene 5-positive dermatomyositis","volume":"72","author":"Tsuji","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"2023010522252613000_49.12.1356.13","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key188"},{"key":"2023010522252613000_49.12.1356.14","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1056\/NEJMc1900045","article-title":"Tofacitinib in amyopathic dermatomyositis-associated interstitial lung disease","volume":"381","author":"Chen","year":"2019","journal-title":"N Engl J Med"},{"key":"2023010522252613000_49.12.1356.15","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468"},{"key":"2023010522252613000_49.12.1356.16","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.165.2.ats01"},{"key":"2023010522252613000_49.12.1356.17","doi-asserted-by":"crossref","unstructured":"So J , So H , Wong VTL , Predictors of rapidly progressive-interstitial lung disease and mortality in patients with autoantibodies against melanoma differentiation-associated protein 5 dermatomyositis. Rheumatology 2022 Feb 14 (Epub ahead of print).","DOI":"10.1093\/rheumatology\/keac094"},{"key":"2023010522252613000_49.12.1356.18","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201604-0801CI"},{"key":"2023010522252613000_49.12.1356.19","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2462070712"},{"key":"2023010522252613000_49.12.1356.20","first-page":"707","article-title":"Favorable outcomes with tacrolimus in two patients with refractory interstitial lung disease associated with polymyositis\/dermatomyositis","volume":"23","author":"Ochi","year":"2005","journal-title":"Clin Exp Rheumatol"},{"key":"2023010522252613000_49.12.1356.21","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161217"},{"key":"2023010522252613000_49.12.1356.22","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1093\/rheumatology\/kez394","article-title":"Impact of adding tacrolimus to initial treatment of interstitial pneumonitis in polymyositis\/dermatomyositis: a single-arm clinical trial","volume":"59","author":"Takada","year":"2020","journal-title":"Rheumatology"},{"key":"2023010522252613000_49.12.1356.23","doi-asserted-by":"publisher","DOI":"10.2174\/0929867003374723"},{"key":"2023010522252613000_49.12.1356.24","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev192"},{"key":"2023010522252613000_49.12.1356.25","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1111\/resp.13978","article-title":"Prednisolone and tacrolimus versus prednisolone and cyclosporin A to treat polymyositis\/dermatomyositis-associated ILD: a randomized, open-label trial","volume":"26","author":"Fujisawa","year":"2021","journal-title":"Respirology"},{"key":"2023010522252613000_49.12.1356.26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109071"},{"key":"2023010522252613000_49.12.1356.27","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/j.cgh.2018.11.035","article-title":"Safety of tofacitinib for treatment of ulcerative colitis, based on 4.4 years of data from global clinical trials","volume":"17","author":"Sandborn","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2023010522252613000_49.12.1356.28","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1080\/1744666X.2018.1512404","article-title":"Tofacitinib for the treatment of psoriasis and psoriatic arthritis","volume":"14","author":"Berekmeri","year":"2018","journal-title":"Expert Rev Clin Immunol"},{"key":"2023010522252613000_49.12.1356.29","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/bjd.18606","article-title":"Open-label pilot study of tofacitinib 2% for the treatment of refractory vitiligo","volume":"182","author":"Mobasher","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023010522252613000_49.12.1356.30","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1001\/jamadermatol.2016.0866","article-title":"Tofacitinib citrate for refractory cutaneous dermatomyositis: an alternative treatment","volume":"152","author":"Kurtzman","year":"2016","journal-title":"JAMA Dermatol"},{"key":"2023010522252613000_49.12.1356.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.08.009"},{"key":"2023010522252613000_49.12.1356.32","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1002\/art.41602","article-title":"Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients","volume":"73","author":"Paik","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"2023010522252613000_49.12.1356.33","doi-asserted-by":"crossref","first-page":"274","DOI":"10.55563\/clinexprheumatol\/di1083","article-title":"Clinical spectrum time course in non-Asian patients positive for anti-MDA5 antibodies","volume":"40","author":"Cavagna","year":"2022","journal-title":"Clin Exp Rheumatol"},{"key":"2023010522252613000_49.12.1356.34","doi-asserted-by":"crossref","first-page":"536","DOI":"10.3109\/14397595.2015.1014140","article-title":"A case of anti-MDA5-positive rapidly progressive interstitial lung disease in a patient with clinically amyopathic dermatomyositis ameliorated by rituximab, in addition to standard immunosuppressive treatment","volume":"27","author":"Yamaguchi","year":"2017","journal-title":"Mod Rheumatol"},{"key":"2023010522252613000_49.12.1356.35","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1007\/s10067-018-4122-2","article-title":"Rituximab for refractory rapidly progressive interstitial lung disease related to anti-MDA5 antibody-positive amyopathic dermatomyositis","volume":"37","author":"So","year":"2018","journal-title":"Clin Rheumatol"},{"key":"2023010522252613000_49.12.1356.36","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1093\/rheumatology\/kez357","article-title":"Successful treatment of anti-MDA5 antibody-positive refractory interstitial lung disease with plasma exchange therapy","volume":"59","author":"Abe","year":"2020","journal-title":"Rheumatology"},{"key":"2023010522252613000_49.12.1356.37","doi-asserted-by":"crossref","first-page":"361","DOI":"10.3109\/14397595.2013.852847","article-title":"Favorable outcome with hemoperfusion of polymyxin B-immobilized fiber column for rapidly progressive interstitial pneumonia associated with clinically amyopathic dermatomyositis: report of three cases","volume":"24","author":"Ichiyasu","year":"2014","journal-title":"Mod Rheumatol"},{"key":"2023010522252613000_49.12.1356.38","doi-asserted-by":"crossref","first-page":"742823","DOI":"10.3389\/fmed.2021.742823","article-title":"Case report: extracorporeal membrane oxygenation for rapidly progressive interstitial lung disease associated with clinically amyopathic dermatomyositis in a post-partum woman","volume":"8","author":"Gu","year":"2021","journal-title":"Front Med"},{"key":"2023010522252613000_49.12.1356.39","first-page":"6097183","article-title":"Spontaneous pneumomediastinum due to anti-melanoma differentiation-associated protein 5 requiring a bilateral lung transplant","volume":"2021","author":"Jhajj","year":"2021","journal-title":"Case Rep Rheumatol"}],"container-title":["The Journal of Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.3899\/jrheum.220367","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T06:43:53Z","timestamp":1672987433000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.jrheum.org\/lookup\/doi\/10.3899\/jrheum.220367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,15]]},"references-count":39,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,1]]},"published-print":{"date-parts":[[2022,12]]}},"alternative-id":["10.3899\/jrheum.220367"],"URL":"https:\/\/doi.org\/10.3899\/jrheum.220367","relation":{},"ISSN":["0315-162X","1499-2752"],"issn-type":[{"value":"0315-162X","type":"print"},{"value":"1499-2752","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,15]]}}}